Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReSPONSE: Etanercept management strategies in plaque psoriasis
NCT00992394Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jan 2010
- Primary completion
- Apr 2013
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
Phase 4, randomised, open-label trial of etanercept in plaque psoriasis (2 arms), sponsored by Pfizer. Primary endpoint: Time-Normalized Area Under Curve of Physician Global Assessment of Psoriasis Score at 52 weeks. Started Jan 2010; status: completed.
02
Drugs
etanercept
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00992394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00992394.